Competition from within
Published in eyeforpharma July 29 by Rachel Howard
To what extent can Big Pharma expect to face an increasing challenge from globalizing pharmaceutical companies based in emerging markets?
If we take a look at the top 50 pharmaceutical companies of 2013, they are mainly headquartered in North America (18), the EU (18) or Japan (9). Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy - which have since merged - the only representation from the ‘BRIC’ markets (Brazil, Russia, India and China). In ten years’ time, will more ‘home-grown’ emerging market companies feature on this list?
In this article, I will explore and compare the directions the domestic pharmaceutical industries of South Korea, China and Brazil have taken in recent years, and consider what threat, if any, each poses to established pharmaceutical companies on a global scale.
AAD Conference 2015
Is early biologic treatment enough to ensure optimal patient outcomes?
We are delighted to be presenting a poster at this year’s annual dermatology conference, AAD, which is taking place in New York on August 20-22.
Could ‘around the pill’ solutions be the key to effective diabetes management?
Published in pharmaphorum July 2015 by Julie Denny
Research with patients shows that they have particular needs at specific stages, from diagnosis to longer-term disease management, that pharma and technology could address.
In the crowded type 2 diabetes market, pharma companies need to find other ways, beyond blood glucose control, to differentiate their brands. In an effort to stand out, players such as Janssen have developed 'around the pill' support programmes that aim to help patients address the health and lifestyle issues which are causing them to struggle to maintain management of their disease.
Richard Head and An-hwa Lee appointed new EphMRA positions
We are pleased to announce that Director Richard Head has been re-elected to the EphMRA Executive Board 2015 and Associate Director An-hwa Lee to the Learning and Development committee
Richard is championing innovation at Research Partnership, and in his time as board member, Richard has been an active voice for Associate Members. The board, which includes both pharmaceutical company and supplier side representation, helps to determine where EphMRA should focus in order to best benefit its members.For 2015-17, Richard aims to advance his existing efforts, and commented, “I am delighted to continue to represent all Associate Members, from full service agencies to syndicated data suppliers and fieldwork providers, on the EphMRA board. I am passionate about maintaining the highest standards in market research, as expected from EphMRA, advocating the use of innovative technologies and solutions. I look forward to working with my fellow board members to advance EphMRA’s strategic goals.”
China: The Future Of Pharmaceutical Industry Innovation?
Published in Medical Marketing & Media, July 2015
I recently visited a London art gallery in which one of the so-called Old Masters had been replaced by a “Made in China” replica. The gallery invited members of the public to try to identify which painting was not authentic. Although in the West replica art is typically denigrated as “fake,” perceptions are very different in China, where such art is considered aspirational. The exhibition made me think about the parallels between the art world and the pharmaceutical industry, in terms of perceptions of Chinese-made drugs versus Big Pharma.
The most obvious parallel to draw would be counterfeit pharmaceuticals originating from China. This is a business globally estimated by WHO to be worth $75 billion US dollars a year and rising. Counterfeit drugs are a huge problem in emerging markets and China is no exception. Outside of the art world, the country already has a long-standing reputation for producing inferior and counterfeit goods, from imitation Louis Vuitton bags to copycat smart phones.